study confirmed the existence of molecular subtypes of DLBCL; evidence that genomic tests have prognostic significance in non-selected DLBCL given; novelty was the division of the previously identified SGK1 cluster into SOCS1/SGK1 and TET2/SGK1 subgroups; the biological validity supported by the enrichment of JAK/STAT and ERK gene expression signatures; limitation: the lack of BCL6 fusion data. Here, SOCS1 is linked to diffuse large B-cell lymphoma.